Celldex Therapeutics, Inc. (CLDX) Scorecard
- 2026-Q2: Total return Win; Revenue growth Lose; EPS growth Lose.
- 2026-Q1: Total return Win; Revenue growth Lose; EPS growth Win.
- 2025-Q4: Total return Win; Revenue growth Lose; EPS growth Win.
- 2025-Q3: Total return Win; Revenue growth Lose; EPS growth Win.
46/120
All 120 Win/Lose results shown below
Every strict quarterly win earns 1 point. A loss, tie, or unavailable scoring value earns 0.
Trailing 1 year (4 quarters): 7 wins, 5 lossesLast fetched: 4 Sept 2026
Complete point ledger
Each cell identifies the missing side explicitly.
| Quarter | Total return | Revenue growth | EPS growth |
|---|---|---|---|
| 2026-Q21/3 |
WinCLDX / S&P 17.31% / 15.20% |
LoseCLDX / S&P CLDX unavailable / 15.00% |
LoseCLDX / S&P 44.85% / 50.40% |
| 2026-Q12/3 |
WinCLDX / S&P 16.79% / -4.33% |
LoseCLDX / S&P CLDX unavailable / 11.30% |
WinCLDX / S&P 58.15% / 27.70% |
| 2025-Q42/3 |
WinCLDX / S&P 4.99% / 2.65% |
LoseCLDX / S&P CLDX unavailable / 9.00% |
WinCLDX / S&P 59.18% / 13.40% |
| 2025-Q32/3 |
WinCLDX / S&P 27.13% / 8.12% |
LoseCLDX / S&P CLDX unavailable / 4.61% |
WinCLDX / S&P 31.01% / 13.45% |
| 2025-Q21/3 |
WinCLDX / S&P 12.12% / 10.94% |
LoseCLDX / S&P -30.25% / 4.83% |
LoseCLDX / S&P 9.45% / 10.63% |
| 2025-Q11/3 |
LoseCLDX / S&P -28.18% / -4.27% |
WinCLDX / S&P 24.49% / 4.98% |
LoseCLDX / S&P -5.59% / 10.57% |
| 2024-Q40/3 |
LoseCLDX / S&P -25.65% / 2.41% |
LoseCLDX / S&P 1.99% / 5.25% |
LoseCLDX / S&P -16.10% / 6.15% |
| 2024-Q31/3 |
LoseCLDX / S&P -8.16% / 5.89% |
WinCLDX / S&P 128.55% / 5.89% |
LoseCLDX / S&P -2.64% / 6.11% |
| 2024-Q22/3 |
LoseCLDX / S&P -11.82% / 4.28% |
WinCLDX / S&P 155.05% / 5.38% |
WinCLDX / S&P 14.11% / 5.12% |
| 2024-Q12/3 |
LoseCLDX / S&P 5.82% / 10.56% |
WinCLDX / S&P 92.76% / 5.71% |
WinCLDX / S&P 13.04% / 5.59% |
| 2023-Q43/3 |
WinCLDX / S&P 44.11% / 11.69% |
WinCLDX / S&P 192.02% / 6.81% |
WinCLDX / S&P 21.67% / 7.78% |
| 2023-Q32/3 |
LoseCLDX / S&P -18.89% / -3.27% |
WinCLDX / S&P 304.92% / 7.52% |
WinCLDX / S&P 17.26% / -5.03% |
| 2023-Q22/3 |
LoseCLDX / S&P -5.70% / 8.74% |
WinCLDX / S&P 295.02% / 9.50% |
WinCLDX / S&P 12.62% / -8.57% |
| 2023-Q11/3 |
LoseCLDX / S&P -19.27% / 7.50% |
LoseCLDX / S&P -23.93% / 10.77% |
WinCLDX / S&P 47.95% / -15.69% |
| 2022-Q42/3 |
WinCLDX / S&P 58.56% / 7.56% |
LoseCLDX / S&P -49.33% / 11.88% |
WinCLDX / S&P 46.34% / -17.99% |
| 2022-Q31/3 |
WinCLDX / S&P 4.27% / -4.88% |
LoseCLDX / S&P -86.70% / 13.47% |
LoseCLDX / S&P CLDX unavailable / -1.41% |
| 2022-Q20/3 |
LoseCLDX / S&P -20.85% / -16.10% |
LoseCLDX / S&P -90.44% / 13.71% |
LoseCLDX / S&P CLDX unavailable / 11.04% |
| 2022-Q10/3 |
LoseCLDX / S&P -11.85% / -4.60% |
LoseCLDX / S&P -22.94% / 15.97% |
LoseCLDX / S&P CLDX unavailable / 42.23% |
| 2021-Q40/3 |
LoseCLDX / S&P -28.43% / 11.03% |
LoseCLDX / S&P -37.28% / 15.00% |
LoseCLDX / S&P CLDX unavailable / 96.40% |
| 2021-Q32/3 |
WinCLDX / S&P 61.45% / 0.58% |
WinCLDX / S&P 79.31% / 10.77% |
LoseCLDX / S&P CLDX unavailable / 69.42% |
| 2021-Q22/3 |
WinCLDX / S&P 62.33% / 8.55% |
WinCLDX / S&P 96.00% / 6.58% |
LoseCLDX / S&P CLDX unavailable / 51.81% |
| 2021-Q12/3 |
WinCLDX / S&P 17.58% / 6.17% |
WinCLDX / S&P 10.21% / -1.06% |
LoseCLDX / S&P CLDX unavailable / 7.39% |
| 2020-Q42/3 |
WinCLDX / S&P 18.14% / 12.15% |
WinCLDX / S&P 107.58% / -3.72% |
LoseCLDX / S&P CLDX unavailable / -33.42% |
| 2020-Q32/3 |
WinCLDX / S&P 14.08% / 8.93% |
WinCLDX / S&P 1.55% / -2.04% |
LoseCLDX / S&P CLDX unavailable / -27.10% |
| 2020-Q21/3 |
WinCLDX / S&P 683.13% / 20.54% |
LoseCLDX / S&P -9.25% / -0.46% |
LoseCLDX / S&P CLDX unavailable / -27.11% |
| 2020-Q10/3 |
LoseCLDX / S&P -25.56% / -19.60% |
LoseCLDX / S&P -29.26% / 3.47% |
LoseCLDX / S&P CLDX unavailable / -14.75% |
| 2019-Q40/3 |
LoseCLDX / S&P 4.69% / 9.07% |
LoseCLDX / S&P -62.53% / 5.36% |
LoseCLDX / S&P CLDX unavailable / 2.99% |
| 2019-Q30/3 |
LoseCLDX / S&P -20.52% / 1.70% |
LoseCLDX / S&P -60.37% / 5.02% |
LoseCLDX / S&P CLDX unavailable / 0.21% |
| 2019-Q20/3 |
LoseCLDX / S&P -45.53% / 4.30% |
LoseCLDX / S&P -65.91% / 6.64% |
LoseCLDX / S&P CLDX unavailable / 8.65% |
| 2019-Q11/3 |
WinCLDX / S&P 64.00% / 13.65% |
LoseCLDX / S&P -54.88% / 8.12% |
LoseCLDX / S&P CLDX unavailable / 14.29% |
| 2018-Q40/3 |
LoseCLDX / S&P -55.56% / -13.52% |
LoseCLDX / S&P -25.17% / 9.05% |
LoseCLDX / S&P CLDX unavailable / 18.23% |
| 2018-Q30/3 |
LoseCLDX / S&P -10.00% / 7.71% |
LoseCLDX / S&P 0.61% / 10.21% |
LoseCLDX / S&P CLDX unavailable / 19.06% |
| 2018-Q21/3 |
LoseCLDX / S&P -78.54% / 3.43% |
WinCLDX / S&P 50.29% / 9.03% |
LoseCLDX / S&P CLDX unavailable / 14.46% |
| 2018-Q11/3 |
LoseCLDX / S&P -17.96% / -0.76% |
WinCLDX / S&P 117.75% / 7.68% |
LoseCLDX / S&P CLDX unavailable / 12.46% |
| 2017-Q41/3 |
LoseCLDX / S&P -0.70% / 6.64% |
WinCLDX / S&P 87.81% / 7.03% |
LoseCLDX / S&P CLDX unavailable / 13.82% |
| 2017-Q32/3 |
WinCLDX / S&P 15.79% / 4.48% |
WinCLDX / S&P 66.49% / 5.68% |
LoseCLDX / S&P CLDX unavailable / 17.57% |
| 2017-Q21/3 |
LoseCLDX / S&P -31.58% / 3.09% |
WinCLDX / S&P 71.65% / 4.83% |
LoseCLDX / S&P CLDX unavailable / 17.74% |
| 2017-Q11/3 |
LoseCLDX / S&P 1.98% / 6.07% |
WinCLDX / S&P 11.40% / 3.67% |
LoseCLDX / S&P CLDX unavailable / 13.32% |
| 2016-Q41/3 |
LoseCLDX / S&P -12.38% / 3.82% |
WinCLDX / S&P 23.79% / 2.09% |
LoseCLDX / S&P CLDX unavailable / 7.05% |
| 2016-Q31/3 |
LoseCLDX / S&P -7.97% / 3.85% |
WinCLDX / S&P 29.73% / 0.20% |
LoseCLDX / S&P CLDX unavailable / -3.15% |
Dividend-reinvested, split-adjusted total return
1Y · 2025-08-29 to 2026-08-27
| Metric | CLDX total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | 83.24% | 20.78% |
| Annualized return | 83.24% | 20.78% |
5Y · 2021-09-01 to 2026-08-27
| Metric | CLDX total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -24.84% | 83.14% |
| Annualized return | -5.55% | 12.86% |
10Y · 2016-09-01 to 2026-08-27
| Metric | CLDX total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -19.72% | 319.30% |
| Annualized return | -2.17% | 15.41% |
Calculation rules
- window
- Latest 40 completed benchmark quarters; unavailable issuer evidence remains visible and scores 0.
- return Basis
- Issuer adjusted close reinvests distributions and normalizes splits; the S&P 500 Total Return Index is the direct benchmark.
- point Rule
- Strict same-quarter win = 1. Loss, tie or unavailable evidence = 0. No partial or subjective points.
- frequency
- Quarter endpoints only.
- fundamentals
- Trailing-four-quarter issuer revenue and EPS growth use the issuer's normalized government-filed facts.
- non Scoring
Snapshot captured 2026-09-04.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEOGEN CORP (NEOG) | United States | $2.979B | -247.49 |
| Intellia Therapeutics, Inc. (NTLA) | United States | $1.705B | -5.92 |
| ACHIEVE LIFE SCIENCES, INC. (ACHV) | United States | $0.806B | -5.88 |
| QuidelOrtho Corp (QDEL) | United States | $0.733B | -0.90 |
| Alpha Teknova, Inc. (TKNO) | United States | $0.500B | -18.12 |
| MYRIAD GENETICS INC (MYGN) | United States | $0.397B | -4.84 |
| Insight Molecular Diagnostics Inc. (IMDX) | United States | $0.129B | -3.90 |
| IMMUCELL CORP /DE/ (ICCC) | United States | $0.091B | 116.10 |
| BIOMERICA INC (BMRA) | United States | $0.011B | |
| Q/C TECHNOLOGIES, INC. (QCLS) | United States | $0.008B | -1.93 |